Mediterranean Diet May Modestly Reduce Risk for Obesity-Related Cancers
Inmaculada Aguilera-Buenosvinos, Ph.D., from the University of Navarra in Spain, and colleagues examined the association between adherence to the MedDiet and the risk for ORCs. The analysis included data from 450,111 participants (mean age, 51.1 years) in the European Prospective Investigation Into Cancer and Nutrition study.
Rapid Gene Test Aids Brain Cancer Surgery
WEDNESDAY, Feb. 26, 2025 (HealthDay News) — A rapid experimental genetic test can help guide the hands of surgeons as they delicately remove tumors from patients with brain cancer, new research suggests.
Talazoparib + Enzalutamide Tied to Improved Overall Survival in Metastatic Prostate Cancer
WEDNESDAY, Feb. 19, 2025 (HealthDay News) — For patients with metastatic castration-resistant prostate cancer (mCRPC) unselected for homologous recombination repair (HRR) gene alterations, talazoparib (TALA) + enzalutamide (ENZA) is associated with improved overall survival versus placebo + ENZA, according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 13 to 15 in San Francisco.
Testosterone Recovery Linked to Overall Survival in High-Risk Prostate Cancer
TUESDAY, Feb. 18, 2025 (HealthDay News) — Serum testosterone (T) recovery to normal levels is associated with a significant improvement in overall survival in patients with high-risk prostate cancer receiving radiotherapy and long-term androgen deprivation therapy (ADT), according to a study presented at the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb. 13 to 15 in San Francisco.
AI Contributes to Early Detection of Clinically Relevant Breast Cancer
THURSDAY, Feb. 13, 2025 (HealthDay News) — Artificial intelligence (AI) contributes to early detection of clinically relevant breast cancer, according to a study published online Feb. 3 in The Lancet Digital Health.
Urine-Based Test Provides Accurate Testing Option for Advanced Prostate Cancer
The 18-gene MyProstateScore 2.0 (MPS2) test using first-catch non-digital rectal examination (DRE) urine is highly sensitive for grade group (GG) ≥2 prostate cancer and can improve the proportion of biopsies avoided.
The Pill Protects Against Ovarian Cancer, Study Says
WEDNESDAY, Feb. 5, 2025 (HealthDay News) — The Pill prevents pregnancy — and maybe ovarian cancer, too, a new study suggests.
GLP-1 RAs Tied to Higher Thyroid Cancer Risk in First Year of Treatment
THURSDAY, Jan. 30, 2025 (HealthDay News) — The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1
Daily Aspirin Reduces Colon Cancer Risk: Study
WEDNESDAY, Jan. 29, 2025 (HealthDay News) — Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new stu
Multiparametric MRI Expedites Treatment in Muscle-Invasive Bladder Cancer
FRIDAY, Jan. 24, 2025 (HealthDay News) — Incorporating multiparametric magnetic resonance imaging (mpMRI) for initial staging can reduce the time to correct tr
No Link Seen Between GLP-1 Receptor Agonist Use and Thyroid Cancer
WEDNESDAY, Jan. 22, 2025 (HealthDay News) — Glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is not associated with an increased risk for thyroid cancer
Talquetamab Plus Teclistamab Shows Promise in Multiple Myeloma
THURSDAY, Jan. 9, 2025 (HealthDay News) — For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high perc
